Press Release – 12 November 2026, Mumbai
1Crowd, an Indian sector‑agnostic early‑stage investment fund, announced that Rymo Technologies has joined its healthcare and medtech portfolio. The announcement was made on 12 November 2026 in Mumbai.
Rymo Technologies is a health‑tech company that develops technology‑led physical rehabilitation solutions using robotics, artificial intelligence (AI) and gamification. Its product suite includes the Mobi‑L and Mobi‑L Pro robotic rehabilitation systems, the Mend and Mend Pro balance trainers, the Aura XR extended‑reality (XR) and virtual‑reality (VR) platform, functional electrical stimulation (FES) devices, and a robotic platform marketed under the Axonym brand. All products are designed for hospitals, physiotherapy clinics and rehabilitation centres, targeting patients recovering from neurological and orthopaedic conditions.
The company positions its solutions as highly affordable, costing only 10 % to 20 % of imported robotic rehabilitation systems that typically range from ₹1 crore to ₹1.5 crore. By offering prices roughly ten times lower than foreign competitors, Rymo aims to serve the long tail of smaller physiotherapy centres and mid‑sized hospitals that face budget, space and staffing constraints.
Natasha Kothari, Co‑Founder and Partner at 1Crowd, said the fund looks to back businesses that use technology to close real gaps in access and delivery, and that Rymo’s approach to affordable, advanced rehabilitation technology aligns with the opportunity in this space. Chirag Shah, Co‑Founder and CEO of Rymo, reiterated the vision of making high‑quality rehabilitation more effective, engaging and accessible through robotics, AI and gamification.
Healthcare and medtech investments account for close to 20 % of 1Crowd’s overall investment portfolio. To date, the fund has backed around ten companies across the broader health‑tech ecosystem—including health technology, biotechnology, healthcare insurance and financing, and medical devices—and has invested in 58 startups across more than 120 investment rounds since its inception in 2015.
Rymo holds ISO 13485 quality certification and is expanding its presence across India while building international partnerships and ongoing clinical collaborations with academic and healthcare institutions.